Affordable Access

deepdyve-link
Publisher Website

Vaccine safety surveillance informs public health policy beyond immunization: A case-series on bleeding following vaccination, Nepal, 2016–2018

Authors
  • Pradhan, Rahul1
  • Sharma Gautam, Jhalak2
  • Tinkari, Bhim Singh2
  • Adhikari, Neelam3
  • Bose, Anindya Sekhar1
  • 1 WHO Country Office, Nepal
  • 2 Family Welfare Division, Department of Health Services, Ministry of Health and Population, Nepal
  • 3 National AEFI Investigation Committee, C/O Family Welfare Division, Department of Health Services, Ministry of Health and Population, Nepal
Type
Published Article
Journal
Vaccine
Publisher
Elsevier Science
Publication Date
Sep 11, 2020
Volume
38
Issue
40
Pages
6320–6326
Identifiers
DOI: 10.1016/j.vaccine.2020.07.035
PMID: 32788134
PMCID: PMC7482439
Source
PubMed Central
Keywords
License
Unknown

Abstract

Background Surveillance for adverse events following immunization (AEFI) is important to monitor vaccine safety and should lead to appropriate responses to improve health and immunization program. Bleeding following vaccination is not recognized as an important AEFI. Without policy of vitamin K (VK) prophylaxis at birth, vitamin K deficiency bleeding (VKDB) could be an important cause of bleeding in young infants and may manifest as AEFI. Methods We retrospectively analysed all serious AEFI cases that presented with external or internal bleeding reported to Nepal’s AEFI surveillance system during 2016–2018. The cases were classified as VKDB, suspected VKDB or non-VKDB. Results During the period, 16 serious AEFI with symptom or sign of bleeding were reported representing 21.3% of all serious AEFI reported. Cases were between 40 and 94 days of age. The National AEFI Investigation Committee classified all cases as coincidental. Fourteen cases (87.5%) had bleeding from injection site. Median time from vaccination to injection site bleeding was 4.3 h (interquartile range: 2.1–11.6 h). Six cases (37.5%) had intra-cranial haemorrhage. Only one case had confirmed history of receiving VK at birth. Ten cases (62.5%) received appropriate treatment (VK injection; blood transfusion if needed). Based on limited laboratory investigations available, three cases (18.75%) could be classified as late onset VKDB and 11 cases (68.75%) as suspected late onset VKDB. Conclusion VKDB should be suspected in young infants presenting with bleeding including following vaccination, and prompt treatment should be initiated. Bleeding following vaccination should be recognized as an important AEFI as even a small amount of blood loss in young infants can be catastrophic. We posit that this series is a small subset of VKDB cases in Nepal detected through AEFI surveillance system. In countries without policy of VK prophylaxis at birth including Nepal, the policy should be introduced.

Report this publication

Statistics

Seen <100 times